Survival Outcomes in Real-World Settings After Alternative Pembrolizumab Dosing for NCSLC

Yakup Ergün, Medical Oncologist at Bower Hospital, shared a post on X, about recent paper published in Lung Cancer:

Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective.

Authors: Geeske Grita, Esmée van Geffen, Ruben Malmberg, Roelof van Leeuwen, Stefan Böhringer, Hans JM Smith, Pepijn Brocken, Job FH Eijsink, Esther Dronkers, Pim Gal, Eva Jaarsma, Regine JHM van Drie-Pierik, Anne MP Eldering-Heldens, AN Machteld Wymenga, Peter GM Mol, Juliëtte Zwaveling, Doranne Hilarius.

”Real-world overall survival after alternative dosing for pembrolizumab in the treatment of NCSLC.

In this RWD involving 1996 patients, low-dose pembrolizumab significantly reduces costs without compromising efficacy.”

Source: Yakup Ergün/X